China NMPA Drug Inspection - Shaanxi Renkang Pharmaceutical Co., Ltd. - Blood-stasis-removing and freckle-removing capsules
China NMPA drug inspection for Shaanxi Renkang Pharmaceutical Co., Ltd. published October 31, 2019. Drug: Blood-stasis-removing and freckle-removing capsules. The Hubei Province Drug Administration released findings from its First Round of Drug Sampling Inspections conducted in
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Shaanxi Renkang Pharmaceutical Co., Ltd. published October 31, 2019. Drug: Blood-stasis-removing and freckle-removing capsules. The Hubei Province Drug Administration released findings from its First Round of Drug Sampling Inspections conducted in
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox